Biosceptre has established a strong IP portfolio around nfP2X7, our validated, proprietary oncology target. Our IP delivers a platform for oncology immunotherapy spanning a range of therapeutic modalities.

Early research suggests that drugs directed to nfP2X7 have the potential to treat multiple cancers whilst avoiding the toxicity seen with many marketed cancer drugs.

Biosceptre Pipeline of Therapeutics targeting nfP2X7.


The most advanced of Biosceptre’s development programmes is BIL010t, a topical formulation, polyclonal antibody, to treat basal cell carcinoma (BCC), advanced BCC, and other skin cancers. This programme has delivered excellent safety and tolerability data alongside a strong indication of efficacy in man.

Biosceptre’s second core program is BIL03s, a domain antibody for systemic administration to treat a variety of tumours is about to enter a Phase I clinical trial.

The third program, BIL06v, is a therapeutic anti-cancer vaccine which has entered preclinical development.

Biosceptre’s proprietary target nfP2X7 has important potential advantages over current chemotherapy, radiation treatments and other oncology immunotherapies including:

  • Targeted mechanism of action towards a receptor over-expressed on cancer cells and absent from the surface of normal cells
  • Potential application across a broad range of cancer types, including breast, prostate, lung, melanoma and bladder cancers
  • Low off target toxicity benefits

In addition, detection of nfP2X7 has potential as a powerful diagnostic approach. Therefore, Biosceptre is also investigating development  of  companion diagnostics based on targeting nfP2X7.